Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Novartis logo

Novartis

Status and phase

Active, not recruiting
Phase 1

Conditions

Gastroesophageal Cancer
Renal Cell Carcinoma
Colorectal Cancer

Treatments

Drug: FOLFIRI
Drug: Paclitaxel
Drug: Gevokizumab
Drug: Bevacizumab
Drug: Modified FOLFOX6
Drug: Cabozantinib
Drug: Ramucirumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT03798626
CVPM087A2101
2018-003952-19 (EudraCT Number)

Details and patient eligibility

About

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.

Enrollment

167 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.
  • Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1.

For Cohort A:

- First line metastatic colorectal cancer.

For Cohort B:

- Second line metastatic colorectal cancer that has progressed on prior chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin.

For Cohort C:

- Second line metastatic gastroesophageal cancer that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet.

For Cohort D:

- Second or third line metastatic renal cell carcinoma with a clear-cell component and has received one or two lines of treatment for metastatic disease that included an anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

For subjects starting from Part 1a in Cohorts A and B:

  • Serum hs-CRP at screening ≥ 10 mg/L.
  • Not requiring immediate initiation of anti-cancer therapy per investigator's best judgement.

For subjects starting from Part 2 in Cohort C:

- Serum hs-CRP at screening ≥ 10 mg/L.

Exclusion criteria

For All Cohorts:

  • Currently receiving any of the prohibited medications or has contraindications as outlined in the protocol.
  • Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery).
  • Suspected or proven immunocompromised state, or infections (as defined in the protocol).
  • Conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents.
  • Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease.

For Cohort D:

  • Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
  • Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib.

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

167 participants in 4 patient groups

Cohort A: 1st line colorectal cancer
Experimental group
Description:
Treatment for 1st line metastatic colorectal cancer (mCRC) with Gevokizumab, modified FOLFOX6, bevacizumab
Treatment:
Drug: Modified FOLFOX6
Drug: Bevacizumab
Drug: Gevokizumab
Cohort B: 2nd line colorectal cancer
Experimental group
Description:
Treatment for 2nd line mCRC with Gevokizumab, FOLFIRI, bevacizumab
Treatment:
Drug: Bevacizumab
Drug: Gevokizumab
Drug: FOLFIRI
Cohort C: 2nd line gastroesophageal cancer
Experimental group
Description:
Treatment for 2nd line metastatic gastroesophageal cancer (mGEC) with Gevokizumab, paclitaxel, ramucirumab
Treatment:
Drug: Ramucirumab
Drug: Gevokizumab
Drug: Paclitaxel
Cohort D: 2nd or 3rd line renal cell carcinoma
Experimental group
Description:
Treatment for 2nd or 3rd line metastatic renal cell carcinoma (mRCC) with Gevokizumab, cabozantinib
Treatment:
Drug: Cabozantinib
Drug: Gevokizumab

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems